Superior Quality MK2866(Ostarine)Powder For Bodybuilding CAS:841205-47-8

    What Is MK2866 (Ostarine)?

    MK2866, more commonly known as Ostarine, is a compound that sits at the intersection of pharmaceutical research and athletic performance optimization. Technically designated as a Selective Androgen Receptor Modulator, Ostarine was originally synthesized by the pharmaceutical company GTx, Inc. with a very specific medical mission in mind: to combat muscle-wasting conditions such as sarcopenia, cancer cachexia, and osteoporosis. Its full chemical identity carries several aliases-Enobosarm, GTx-024, VERU-024-each reflecting a different chapter in its research journey.

    The molecular architecture of Ostarine is what makes it fundamentally distinct from the anabolic steroids that have dominated bodybuilding culture for decades. Unlike steroids, which flood the body with androgenic activity indiscriminately, MK2866 is engineered to "knock" selectively on the doors of androgen receptors located primarily in skeletal muscle and bone tissue. This selectivity is not marketing hype-it is rooted in the compound's binding affinity. Research indicates that Ostarine binds to the androgen receptor with a Ki value of 3.8 nM, demonstrating potent but targeted activity. In practical terms, this means the compound seeks out muscle tissue while largely bypassing other androgen-sensitive areas such as the prostate and skin.

    From a chemical standpoint, Ostarine presents as a white crystalline powder, odorless with a mild taste, and carries the CAS number 841205-47-8. Its molecular formula is C19H14F3N3O3, with a molecular weight of approximately 389.33 g/mol. When sourced at superior quality-which typically means purity levels of 98% to over 99%-the powder exhibits consistent crystalline structure and dissolution properties essential for accurate dosing. High-purity Ostarine powder is manufactured through refined synthesis processes that eliminate contaminants and ensure batch-to-batch consistency, a critical factor for anyone considering its application.

    What must be clearly understood is that Ostarine remains an investigational compound. It has not received FDA approval for general human use, and its application outside of approved clinical research is technically unauthorized. The World Anti-Doping Agency classified Ostarine as a prohibited substance back in 2008, placing it squarely in the same regulatory category as traditional anabolic agents. This legal reality does not diminish the compound's pharmacological potency-but it does establish an important boundary between clinical promise and practical application.

    When discussing superior quality MK2866 powder, the conversation must begin with purity. Pharmaceutical-grade Ostarine powder is characterized by purity levels typically exceeding 98%, with some manufacturers offering product purity as high as 99.98%. This level of refinement is not merely a marketing point-it directly impacts the compound's predictability, stability, and the consistency of its pharmacological effects. High-purity powder minimizes the presence of unreacted intermediates, synthesis byproducts, and degradation compounds that could introduce unpredictable variables into the biological response.

    The half-life of Ostarine is another defining feature that shapes how the compound is used. Clinical and pharmacokinetic data consistently place the half-life at approximately 24 hours. This relatively long duration means that once-daily administration is sufficient to maintain stable plasma concentrations throughout a dosing cycle. Unlike compounds with shorter half-lives that require multiple daily doses and produce significant peaks and troughs in blood levels, Ostarine's pharmacokinetic profile supports a smoother, more sustained anabolic signal to muscle tissue.

    Superior quality Ostarine powder is also characterized by its stability under appropriate storage conditions. When kept as a dry powder at room temperature, the compound remains viable for extended periods. For long-term storage, temperatures around -20°C are recommended, where the powder can maintain its integrity for up to three years. This stability profile is particularly relevant for individuals who may purchase powder in bulk and rely on consistent potency over multiple cycles.

    Another feature worth noting is the emergence of esterified variants such as OTR-AC (Ostarine Acetate). This modified form undergoes esterification-a process that combines an organic acid with an alcohol-to alter the compound's release kinetics and potentially extend its duration of action. While standard MK2866 already possesses a favorable half-life, esterified versions represent a further refinement for those seeking even more sustained delivery.

    The original medical applications of Ostarine provide the scientific foundation for its adoption in bodybuilding contexts. Clinical studies involving 968 older adults and postmenopausal women, as well as cancer patients experiencing muscle wasting, have demonstrated that Ostarine produces dose-dependent increases in lean muscle mass accompanied by improvements in physical function. A 12-week randomized clinical trial in postmenopausal women found that Ostarine at 3 mg daily produced comparable efficacy in total lean body mass and muscle strength, while also demonstrating tissue selectivity. Phase II clinical data from cancer cachexia patients showed improvements in stair-climb performance and insulin sensitivity without visible side effects or toxicity.

    In the bodybuilding world, these clinical findings translate into several distinct application contexts:

    Muscle Preservation During Caloric Deficits. Perhaps the most valued application of Ostarine in bodybuilding is its ability to preserve lean tissue while the body is in a catabolic state. During cutting phases when caloric intake is reduced, the body naturally shifts toward muscle breakdown for energy. Ostarine counteracts this process by maintaining an anabolic signal to muscle tissue even in the face of a caloric deficit. Users report being able to shed body fat while retaining-and sometimes even modestly increasing-muscle mass.

    Lean Mass Accretion. As the most anabolic SARM in its class, Ostarine is also employed for lean bulking purposes. Unlike traditional bulking agents that often come with significant water retention and fat gain, Ostarine promotes dry, keepable muscle gains. User reports indicate gains of approximately 6 pounds of lean tissue over a 4–6 week period, with the added benefit that these gains are more easily maintained post-cycle compared to those achieved with harsher compounds.

    Injury Recovery and Joint Support. The androgenic activity of Ostarine extends to bone tissue as well as muscle, suggesting potential applications for injury recovery-particularly for bone and tendon-related injuries. Bodybuilders recovering from joint strains or minor connective tissue issues have reported accelerated healing when Ostarine is incorporated into their protocol, though this application remains more anecdotal than rigorously studied.

    Body Recomposition. The nutrient-partitioning effects of Ostarine make it uniquely suited for recomposition cycles-the simultaneous pursuit of muscle gain and fat loss. Users on modest caloric surpluses report that excess calories are directed toward muscle synthesis rather than adipose storage, a phenomenon that speaks to the compound's ability to favorably shift metabolic priorities.

    The benefits attributed to Ostarine by bodybuilding communities span multiple performance and aesthetic dimensions. Increased endurance and stamina are frequently cited, allowing users to extend workout duration and maintain intensity later into training sessions. Faster recovery between workouts is another commonly reported advantage, with users experiencing reduced muscle soreness and the ability to train at higher frequencies.

    Strength gains, while generally more modest than those produced by traditional anabolic steroids, are nevertheless consistent and progressive throughout a cycle. Users report incremental increases in compound lifts without the dramatic-and often unsustainable-strength spikes associated with harsher agents. Enhanced nitrogen retention supports the repair and growth of muscle fibers, particularly following resistance training, while the non-aromatizing nature of Ostarine eliminates concerns about estrogen-related side effects such as gynecomastia or excessive water retention.

    Clinically, the benefits have been quantified. Multiple placebo-controlled human studies demonstrate that Enobosarm at doses of 1–3 mg daily produces statistically significant improvements in lean muscle mass. At higher doses employed by bodybuilders (10–25 mg daily), the magnitude of these effects is amplified, though the risk-benefit calculation shifts accordingly.

    Dosing Ostarine requires careful consideration of experience level, gender, body weight, and specific goals. The clinical data establishes that even 3 mg daily is sufficient to produce measurable increases in lean mass, but bodybuilding applications typically employ higher doses.

    For beginners, a starting dose of 10 mg per day is recommended. This allows the user to assess tolerance while still experiencing noticeable effects. After the first week, the dose may be increased to 15–20 mg if tolerated well. Starting at the lower end of the spectrum is not merely cautious-it is strategic, as the effectiveness of Ostarine does not always increase linearly with higher doses, while the risk of side effects can rise substantially.

    For intermediate users, doses in the range of 15–25 mg per day are typical. This range balances efficacy with manageability and is most commonly cited in user reports as the "sweet spot" for muscle preservation during cutting or modest gains during recomposition phases.

    For advanced users, some protocols push to 30 mg per day, though this is generally considered the upper limit beyond which diminishing returns and increased side effect risk become significant concerns.

    Female users are advised to use significantly lower doses-typically 3–5 mg per day-due to increased sensitivity to androgenic compounds. The female endocrine system responds more readily to exogenous androgenic signaling, and exceeding this range introduces unnecessary risk.

    Regardless of the chosen dose, administration should occur once daily due to the 24-hour half-life. Timing is less critical than consistency, though many users prefer morning dosing to align with natural circadian rhythms of anabolic activity.

    A standard Ostarine cycle typically runs between 8 and 12 weeks, followed by an adequate break to allow for hormonal recovery. Shorter cycles of 4–6 weeks are also common, particularly among first-time users or those employing higher doses. The relationship between cycle length and hormonal suppression is not strictly linear-longer cycles increase the cumulative suppressive effect, but even shorter cycles can produce measurable testosterone decline.

    A typical cycle protocol might look like this:

    Week 1: 10 mg daily (tolerance assessment)
    Weeks 2–8: 15–20 mg daily (maintenance phase)
    Weeks 9–12: 20–25 mg daily (optional extension for advanced users)

    For cutting-specific cycles, lower doses of 12.5–15 mg are often sufficient, as the primary goal is preservation rather than accretion. For bulking or recomposition cycles, the 20–25 mg range is more common.

    Some users employ a tapering strategy, gradually reducing the dose in the final week of the cycle rather than stopping abruptly. While not strictly necessary given the half-life, this approach is thought by some to ease the transition back to endogenous testosterone production, though evidence supporting this practice is largely anecdotal.

    The 24-hour half-life of Ostarine has several practical implications for users. First, it simplifies dosing: one administration per day is sufficient to maintain steady-state plasma levels. Second, it means that approximately five days after the last dose (five half-lives), the compound is effectively cleared from the system. This washout period informs decisions about when to begin post-cycle therapy.

    Steady-state concentrations are typically achieved within 4–5 days of consistent daily dosing. During this initial period, users may not yet perceive the full effects of the compound; patience during the loading phase is important before evaluating results or adjusting doses.

    The long half-life also means that any side effects experienced will persist for a period of days after discontinuation rather than resolving immediately. This reinforces the importance of dose titration and conservative starting points.

    The question of whether Ostarine requires post-cycle therapy is not a simple yes or no. The compound is suppressive to natural testosterone production, though generally less so than traditional anabolic steroids or more potent SARMs like RAD-140 or LGD-4033. The degree of suppression depends on dose, cycle length, and individual physiological factors.

    Mild suppression (typical after 4–6 week cycles at moderate doses) may not require pharmaceutical intervention. Natural testosterone recovery often occurs within 2–4 weeks without exogenous support, though users should monitor for symptoms of low testosterone such as fatigue, reduced libido, or mood changes.

    Moderate to significant suppression (more common after 8–12 week cycles or higher doses) warrants structured PCT. The standard protocol involves a SERM such as Tamoxifen (Nolvadex) at 20 mg daily for 4 weeks, beginning 24 hours after the last Ostarine dose. Some protocols substitute Clomiphene (Clomid) at 25–50 mg daily for a similar duration.

    A noteworthy consideration is that Ostarine has been used by some individuals as part of PCT following cycles of harsher compounds. When employed in this context, low doses of Ostarine (12.5–15 mg) may help preserve muscle mass during the hormonal transition period, though this practice is not without controversy and should be approached with caution.

    Blood work before and after a cycle is the only reliable way to determine the necessity and appropriate duration of PCT. Symptoms alone are poor predictors of underlying hormonal status.

    No discussion of Ostarine would be complete without acknowledging its limitations and risks. Despite being marketed by some as a "safe" alternative to anabolic steroids, Ostarine is a potent pharmacological agent with real potential for adverse effects.

    Testosterone suppression is the most consistently reported side effect. Users report feeling the effects of suppression after a cycle-reduced libido, lethargy, and diminished sense of well-being. The degree of suppression varies widely among individuals, with some experiencing significant declines even at moderate doses.

    Lipid profile alterations have been documented, with Ostarine producing dose-dependent decreases in both LDL and HDL cholesterol. HDL cholesterol-the "good" cholesterol-is particularly vulnerable to suppression by androgenic compounds, and Ostarine is no exception. This cardiovascular risk factor should not be dismissed lightly.

    Hepatotoxicity is generally considered low with Ostarine compared to oral anabolic steroids, but this does not mean the compound is entirely without liver impact. Responsible use includes avoiding concurrent hepatotoxic substances and limiting cycle duration.

    Suppression of the HPTA axis occurs to some degree in all users. The clinical significance of this suppression depends on baseline hormonal status, age, and recovery capacity. Younger users with robust endocrine systems typically recover more quickly and completely than older individuals.

What is often underemphasized in bodybuilding communities is that Ostarine is still under active research. Clinical studies on the effects of its long-term application in healthy humans have not been completed, and unknown risks may yet emerge. The compound has not received FDA approval for any indication, and those who use it for performance enhancement do so outside any regulatory framework for safety monitoring.

Trade names	Ostarine; GTx-024; MK-2866; S-22,Enobosarm
CAS	841205-47-8
Molar mass	389.334
MF	C19H14F3N3O3
Purity	Above 98%
Apprarance	White Crystal Powder

 

 

Any needs, please contact us

Email: Jasonraws106@gmail.com

WhatsApp: +86-15572565525
Telegram: +86-15871669785

   

                                   

 

    Superior quality MK2866 powder represents a fascinating chapter in the evolution of performance-enhancing compounds-a selective agent designed with medical precision that has been repurposed by bodybuilding communities for aesthetic and athletic goals. Its mechanism of selective androgen receptor activation, 24-hour half-life, and relatively mild side effect profile distinguish it from the anabolic steroids that preceded it. For those who choose to use Ostarine, attention to dosage, cycle duration, and post-cycle recovery is essential. But perhaps the most important takeaway is this: Ostarine is a research compound, not a supplement. Its power demands respect, its risks demand awareness, and its use demands informed, deliberate decision-making rather than casual experimentation.

Hot Tags: superior quality mk2866(ostarine)powder for bodybuilding cas:841205-47-8, China superior quality mk2866(ostarine)powder for bodybuilding cas:841205-47-8 manufacturers, suppliers, factory